Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03637049 · ClinicalTrials.gov registry record · Phase 1

Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects

A Phase 1 study of Healthy, sponsored by Liminal BioSciences.

Completed
Registry status
Phase 1
Development phase
22
Enrollment target
1
Study location

NCT03637049: Completed Phase 1 study of Healthy, sponsored by Liminal BioSciences.

NCT03637049 is a Phase 1 study of Healthy that has completed, run by Liminal BioSciences. The registered enrollment target is 22 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03637049, a Phase 1 study of Healthy, has completed, sponsored by Liminal BioSciences.

COMPLETED
Registry status
Phase 1
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of PBI-4050 combined with midazolam in healthy adult subjects.

Conditions Studied

Healthy

Interventions

  • DRUG PBI-4050 and midazolam

Study Locations (1)

Arizona

  • Celerion - Tempe

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2018-07-17
Est. Completion 2018-08-22
Phase Phase 1

Sponsor

Liminal BioSciences

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03637049

The ClinicalTrials.gov registry entry for NCT03637049 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (97% lower). The listed sponsor is Liminal BioSciences, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PBI-4050 and midazolam is the first listed.

NCT03637049 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT03637049 about?

NCT03637049 is a clinical study titled "Effect of PBI-4050 on the Pharmacokinetics of Midazolam in Heathy Adult Subjects". This study is designed to evaluate the pharmacokinetics (PK) and safety of multiple doses of PBI-4050 combined with midazolam in healthy adult subjects.

What is the current status of trial NCT03637049?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-07-17. Estimated completion is 2018-08-22.

What conditions does trial NCT03637049 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT03637049?

The interventions under investigation include: PBI-4050 and midazolam (DRUG).

Who is sponsoring clinical trial NCT03637049?

This trial is sponsored by Liminal BioSciences, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03637049 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Healthy

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.